Acute and subacute effects of the selective serotonin-noradrenaline reuptake inhibitor duloxetine on cardiac hERG channels

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 9, 2013, Pages 795-804

  Fischer, F ^a   Vonderlin, N ^a   Seyler, C ^a   Zitron, E ^a   Schernus, B ^a   Katus, H ^a   Scholz, E ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Acquired long QT syndrome; Arrhythmia; Duloxetine; hERG channels; Repolarization; Selective serotonin noradrenaline reuptake inhibitor (SNRI)

Indexed keywords

DULOXETINE; POTASSIUM CHANNEL HERG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; NONHUMAN; OOCYTE; PROTEIN EXPRESSION; XENOPUS;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ETHER-A-GO-GO POTASSIUM CHANNELS; HEART; HEK293 CELLS; HUMANS; OOCYTES; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; XENOPUS LAEVIS;

EID: 84883253268     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-013-0878-8     Document Type: Article

References (30)

1. Choi J-S, Hahn SJ (2012) Duloxetine blocks cloned Kv4.3 potassium channels. Brain Res 1466:15-23. doi: 10.1016/j.brainres.2012.05.028
2. Curran ME, Splawski I, Timothy KW et al (1995) A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80:795-803
3. Dennis A, Wang L, Wan X, Ficker E (2007) hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans 35:1060-1063. doi: 10.1042/BST0351060
4. Derby MA, Zhang L, Chappell JC et al (2007) The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. J Cardiovasc Pharmacol 49:384-393. doi: 10.1097/FJC.0b013e31804d1cce
5. Ficker E, Kuryshev YA, Dennis AT et al (2004) Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66:33-44. doi: 10.1124/mol.66.1.33
6. Goldstein DJ (2007) Duloxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 3:193-209
7. Kiehn J, Lacerda AE, Brown AM (1999) Pathways of HERG inactivation. Am J Physiol 277:H199-210
8. + channels by different classes of antidepressants. PLoS One 6:e28208. doi: 10.1371/journal.pone.0028208
9. Kuryshev YA, Ficker E, Wang L et al (2005) Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312:316-323. doi: 10.1124/jpet.104.073692
10. Lantz RJ, Gillespie TA, Rash TJ et al (2003) Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 31:1142-1150. doi: 10.1124/dmd.31.9.1142
11. Mitcheson JS, Chen J, Lin M et al (2000) A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97:12329-12333. doi: 10.1073/pnas.210244497
12. Priori SG, Napolitano C (2002) Genetic defects of cardiac ion channels. The hidden substrate for torsades de pointes. Cardiovasc Drugs Ther 16:89-92
13. + channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 149:481-489. doi: 10.1038/sj.bjp.0706892
14. Redfern WS, Carlsson L, Davis AS et al (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32-45
15. Roden DM, Balser JR, George AL, Anderson ME (2002) Cardiac ion channels. Annu Rev Physiol 64:431-475. doi: 10.1146/annurev.physiol.64.083101.145105
16. Sanguinetti MC (2010) HERG1 channelopathies. Pflugers Arch 460:265-276. doi: 10.1007/s00424-009-0758-8
17. Kr potassium channel. Cell 81:299-307
18. Scherer D, Hassel D, Bloehs R et al (2009) Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents. Br J Pharmacol 156:226-236. doi: 10.1111/j.1476-5381.2008.00018.x
19. Scholz EP, Zitron E, Kiesecker C et al (2003) Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired long QT syndrome by antiparkinsonian drug budipine. Naunyn Schmiedebergs Arch Pharmacol 368:404-414. doi: 10.1007/s00210-003-0805-5
20. Scholz EP, Zitron E, Kiesecker C et al (2005) Inhibition of cardiac HERG channels by grapefruit flavonoid naringenin: implications for the influence of dietary compounds on cardiac repolarisation. Naunyn Schmiedebergs Arch Pharmacol 371:516-525. doi: 10.1007/s00210-005-1069-z
21. Scholz EP, Konrad FM, Weiss DL et al (2007) Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656. Naunyn Schmiedebergs Arch Pharmacol 376:275-284. doi: 10.1007/s00210-007-0202-6
22. Scholz EP, Niemer N, Hassel D et al (2009) Biophysical properties of zebrafish ether-à-go-go related gene potassium channels. Biochem Biophys Res Commun 381:159-164. doi: 10.1016/j.bbrc.2009.02.042
23. Sharma A, Goldberg MJ, Cerimele BJ (2000) Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 40:161-167
24. Thase ME, Tran PV, Wiltse C et al (2005) Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 25:132-140
25. + currents. Am J Physiol, Cell Physiol 291:C165-75. doi: 10.1152/ajpcell.00596.2005
26. + channels by antidepressant duloxetine in a state-dependent manner. Anesthesiology 113:655-665. doi: 10.1097/ALN.0b013e3181e89a93
27. Wenzel-Seifert K, Wittmann M, Haen E (2011) QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int 108:687-693. doi: 10.3238/arztebl.2011.0687
28. Wong DT, Bymaster FP, Mayle DA et al (1993) LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 8:23-33
29. Xue F, Strombom I, Turnbull B et al (2012) Treatment with duloxetine in adults and the incidence of cardiovascular events. J Clin Psychopharmacol 32:23-30. doi: 10.1097/JCP.0b013e31823fb238
30. Zhang L, Chappell J, Gonzales CR et al (2007) QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol 49:146-153. doi: 10.1097/FJC.0b013e318030aff7